As part of the National Nuclear Security Administration’s (NNSA) Office of Material Management and Minimization (MMM) Mo-99 Technology Development program, Argonne is helping to accelerate the domestic production of Mo-99.  Molybdenum-99’s daughter decay product, technecium-99m, is used in roughly 80% of all diagnostic nuclear medicine procedures worldwide.  SHINE Medical Technologies is a potential domestic producer and is working to produce an accelerator-driven fission-product Mo-99.  Argonne has designed a Mo-recovery process from 260 L of irradiated uranyl sulfate solution and subsequent Mo concentration process.  The VERSE simulation model was utilized for the design of recovery and concentration columns taking in to account mass transfer, isotherm, and sorbent parameters.  The details of this work along with the results of design verification utilizing uranyl sulfate solution irradiated at the Argonne LINAC will be presented. <br/><br/>

Design of Mo-99 recovery and concentration processes from irradiated uranyl sulfate target solution

251st National Meeting (2016)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.